Navigation Links
Compact KTP laser

ProductsCompact KTP laser
Company Optotek d.o.o
Item Compact KTP laser
Features Minimal damage to surrounding tissue. Well accepted by the patients. Lower IOP within hours. Treatment can be repeated
Description Q-switched, frequency doubled Nd:YAG laser is mounted on Haag Streit slit-lamp. The laser energy can be selected between 0.2 and 2.0 mJ. The spot size can be selected between 400 and 700 microns. Knobs for laser energy and aiming beam intensity are conveniently located on the laser head. The laser system complies with IEC 601 and EC directive 93/42/EEC for medical devices.
Info Optotek d.o.o
Customer Service:

Related medicine products :

1. Compact Ultrasonic Phacoemulsification System
2. Oculus Easyfield Compact Perimeter
3. Compact 30C CO2 Lasers
4. Compact 40C CO2 Lasers
5. Veris Compact
6. Veris Compact™
7. Adams Compact II
8. GR 20.22 Compact High Speed Refrigerated Floor-Standing Centrifuge
9. BR 4i Compact Multi-Function Refrigerated Bench-Top Centrifuge.
10. CR 3i Compact Multi-Function Refrigerated Bench-Top Centrifuge.
11. STA Compact
Precision near-field imaging combined with the best handling IVUS catheter.
Full Digital Ultrasound System
...cho technology constructs images using second harm...and noise than fundamental-frequency components.,...ansmit distortion-free, fundamental-frequency ultr...ltrasound beam is a pure sinusoidal wave, both the...
Aplio was designed for intuitive operation so you can get the results you are looking for quickly and easily. From customizable measurement packages to an ergonomic platform design, Aplio was built m
Medicine Products:
(Date:9/5/2008)...s the Latest Developments in Molecular,Testing and... /PRNewswire-USNewswire/ -- The practice of,pathol...g and the promise,of personalized medicine will ch...and other imaging technologies will change the way...ogists is taking a leadership role in,making sure ...
(Date:9/5/2008)...RNewswire-USNewswire/ -- The Health Resources,and ... million in grants to,increase and improve medical... grants continue President Bush,s historic expansi...w reach more economically,vulnerable and geographi...dministrator Elizabeth M. Duke said. "In 2007, mor...
(Date:9/5/2008)...tical ,anti-cloak, could bring objects out of hidi...-- Just in case someone develops a cloak of invisi... how to uncloak the objects it hides. , Accordi...in materials underneath an invisibility cloak woul...esearchers at Shanghai Jiao Tong University in Chi...
(Date:9/5/2008)...ain to commit to develop a National AIDS,Strategy ...p. 5 /PRNewswire-USNewswire/ -- The,Republican Nat...ion of the,domestic AIDS epidemic in the United St...erseas. Neither Presidential nominee Sen. John McC... mentioned AIDS in their remarks,to Convention del...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3
...in production in mice with type 2 diabetes, demons...ss diabetes, say Tulane University gene// therapy ...week in the Early Edition of the Proceedings of th...lt stem cells are grown from donated human bone ma...
...chnology, Jadavpur University, Kolkata and Departm...ege, Andhra Pradesh done a// study on Plumeria Acu...was to evaluate the anti-inflammatory activity of ...on carrageenan, dextran, histamine and serotonin-i...
...d earlier proved that Policosanols present in Cuba...cts. A new study done by// Canadian researchers co... Peter J. H. Jones and Dr. Amira N. Kassis studyi... the University of Manitoba, Winnipeg, conducted t...
...upport the Public Health Foundation of India (PHFI...c Health in India. PHFI is an autonomous// body. T...ne-time grant upto Rs. 65 crore only to the initia...tially proposes to set up two schools. The locatio...
Other Medicine News:Health News:Anti Inflammatory Evaluation Of Plumeria Acuminata Leaves 2
(Date:9/4/2008)...trates potent antiviral activity and favorable saf...RIDGE, Mass., Sept. 4 /- Id...pharmaceutical company engaged,in the discovery an...viral,and other infectious diseases, today announc...y evaluating IDX899, a non-nucleoside reverse,tran...
(Date:9/3/2008)...stion Asked. Wrong Children Studied. Wrong,Conclus...ewswire/ -- A Centers for Disease,Control and Prev...no link,between the MMR vaccine and autism. The Na...es nothing to dispel the growing public concern ov...questions concerning design,and methodology., For...
(Date:9/3/2008)...s National Vascular Disease Awareness Month, CHAR...n Pharmaceuticals,LLC, a clinical-stage drug-devel...reatment of unmet medical needs, announced today t...I clinical trial of its lead drug,candidate trans ...T00725881,on the clinicaltrials.gov Website, is in...
(Date:9/3/2008)...ny to Discuss Phase 3 Plans with FDA, PRINCETON, ...Inc.,announced today that it successfully complet...he company,s new, innovative low-dose, once-weekly... by its internal product,code AG-200-15. The Phase...,primary endpoint of ovulation suppression, cycle ...
Breaking Medicine Technology:Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 2Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 3Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients 4CDC Misses Target With Flawed MMR/Autism Study 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Patients over age 60 do well after liver transplantation 2645 1Patients over age 60 do well after liver transplantation 2645 2Toy Blocks Might Boost Toddlers Language Skills 2644 1Toy Blocks Might Boost Toddlers Language Skills 2644 2HSN Is Seeing Pink with Susan G Komen for the Cure During National Breast Cancer Awareness Month 2642 1HSN Is Seeing Pink with Susan G Komen for the Cure During National Breast Cancer Awareness Month 2642 2HSN Is Seeing Pink with Susan G Komen for the Cure During National Breast Cancer Awareness Month 2642 3Biomoda President Testifies Before New Mexico Legislature Supporting Clinical Funding for Early Lung Cancer 2640 1Biomoda President Testifies Before New Mexico Legislature Supporting Clinical Funding for Early Lung Cancer 2640 2
...4, 2007 /PRNewswire-FirstCall/ Haemacure,Corporati...mpany,today announced the preliminary findings of...s. , Preliminary findings confirm the presence of ... in significant worldwide,markets, including album...findings take on a strategic significance for Haem...
... 2007 /PRNewswire-FirstCall/ --,Bristol-Myers Squi...fficacy and safety of ORENCIA(R) (abatacept) from ... study in children with juvenile,idiopathic arthri...ne or more disease-modifying anti- rheumatic drugs...rosis factor (TNF) antagonists.,The results demons...
Other Medicine Technology:Haemacure Announces Preliminary Findings of its Plasma Discard,Analysis 2Haemacure Announces Preliminary Findings of its Plasma Discard,Analysis 3Haemacure Announces Preliminary Findings of its Plasma Discard,Analysis 4Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 2Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 3Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 4Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 5Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy 6